Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 8.11% is 517% above its 5-year average of -1.94%, around the middle of its 5-year range (-21.67%–27.64%).
12.21% above its 12-month average of 7.23%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 4.78%.
EBITDA MARGIN
8.11%
EBITDA MARGIN AVG TTM
7.23%
EBITDA MARGIN AVG 3Y
2.07%
EBITDA MARGIN AVG 5Y
-1.94%
EBITDA MARGIN AVG 10Y
-5.51%
EBITDA MARGIN AVG 15Y
-10.95%
EBITDA MARGIN AVG 20Y
-781.79%
CURRENT VS TTM AVG
+12.21%
CURRENT VS 3Y AVG
+292.13%
CURRENT VS 5Y AVG
+517.03%
CURRENT VS 10Y AVG
+247.25%
CURRENT VS 15Y AVG
+174.05%
CURRENT VS 20Y AVG
+101.04%
Market Cap
$2.06B
EBITDA Margin
-18934.67%
TTM Avg
-10834.15%
3Y Avg
-7159.00%
5Y Avg
-5150.48%
Market Cap
$2.06B
EBITDA Margin
-512.27%
TTM Avg
-49559.94%
3Y Avg
-46888.38%
5Y Avg
-33454.98%
Market Cap
$2.02B
EBITDA Margin
39.14%
TTM Avg
19.43%
3Y Avg
-11.55%
5Y Avg
-189.29%
Market Cap
$2.02B
EBITDA Margin
-111.53%
TTM Avg
-109.12%
3Y Avg
-103.85%
5Y Avg
-277.10%
Market Cap
$2.02B
EBITDA Margin
40.34%
TTM Avg
23.31%
3Y Avg
-20.04%
5Y Avg
-112.62%
Market Cap
$2.11B
EBITDA Margin
-4149.30%
TTM Avg
-2232.68%
3Y Avg
-1779.77%
5Y Avg
-1779.77%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vericel Corporation (VCEL) | $2.05B | 8.11% | 7.23% | 2.07% | -1.94% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | -18934.67% | -10834.15% | -7159.00% | -5150.48% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -512.27% | -49559.94% | -46888.38% | -33454.98% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 7.00% | 6.53% | 5.54% | 5.31% |
| Alvotech (ALVO)vs › | $2.08B | 19.79% | 20.20% | -178.47% | -247.76% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | 39.14% | 19.43% | -11.55% | -189.29% |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | -111.53% | -109.12% | -103.85% | -277.10% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 40.34% | 23.31% | -20.04% | -112.62% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | -4149.30% | -2232.68% | -1779.77% | -1779.77% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | N/A | N/A | N/A | N/A |
Gross Margin
74.6%
EBITDA Margin
8.1%
Operating Margin
6.0%
Net Margin
7.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 4.78% |
| 2026-03-31 | -7.01% |
| 2025-12-31 | 27.64% |
| 2025-09-30 | 9.47% |
| 2025-06-30 | 1.26% |
| 2025-03-31 | -19.21% |
| 2024-12-31 | 26.48% |
| 2024-09-30 | -1.97% |
| 2024-06-30 | -8.94% |
| 2024-03-31 | -7.97% |
| 2023-12-31 | 21.36% |
| 2023-09-30 | -8.56% |
| 2023-06-30 | -10.43% |
| 2023-03-31 | -17.11% |
| 2022-12-31 | 13.52% |
| 2022-09-30 | -14.98% |
| 2022-06-30 | -21.67% |
| 2022-03-31 | -17.74% |
| 2021-12-31 | 10.34% |
| 2021-09-30 | -12.41% |
| 2021-06-30 | -7.68% |
| 2021-03-31 | -7.21% |
| 2020-12-31 | 28.79% |
| 2020-09-30 | 12.67% |
| 2020-06-30 | -39.03% |
| 2020-03-31 | -17.03% |
| 2019-12-31 | 24.83% |
| 2019-09-30 | 14.57% |
| 2019-06-30 | -72.94% |
| 2019-03-31 | -12.14% |
| 2018-12-31 | 20.07% |
| 2018-09-30 | -4.52% |
| 2018-06-30 | -20.30% |
| 2018-03-31 | -21.61% |
| 2017-12-31 | 6.93% |
| 2017-09-30 | -25.45% |
| 2017-06-30 | -12.66% |
| 2017-03-31 | -98.43% |
| 2016-12-31 | -32.66% |
| 2016-09-30 | -54.08% |
| 2016-06-30 | -35.14% |
| 2016-03-31 | -10.97% |
| 2015-12-31 | -29.49% |
| 2015-09-30 | -38.62% |
| 2015-06-30 | -14.14% |
| 2015-03-31 | -39.12% |
| 2014-12-31 | -14.21% |
| 2014-09-30 | -80.47% |
| 2014-06-30 | -188.92% |
| 2013-12-31 | -60275.00% |
| 2013-06-30 | -170300.00% |
| 2013-03-31 | -87687.50% |
| 2012-12-31 | -39236.84% |
| 2012-09-30 | -90433.33% |
| 2012-03-31 | -418950.00% |
| 2011-12-31 | -1518.06% |
| 2011-09-30 | -80788.89% |
| 2011-03-31 | -68066.67% |
| 2010-06-30 | 23819.05% |
| 2009-12-31 | -27718.75% |
| 2009-09-30 | -5020.55% |
| 2009-06-30 | -5513.04% |
| 2009-03-31 | -6620.69% |
| 2008-12-31 | -14096.43% |
| 2008-09-30 | -14348.15% |
| 2008-06-30 | -3242.28% |
| 2008-03-31 | -2563.37% |
| 2007-12-31 | -6584.52% |
| 2007-09-30 | -6124.14% |
| 2007-06-30 | -3115.76% |
| 2006-09-30 | -4348.08% |
| 2006-06-30 | -1454.57% |
| 2006-03-31 | -1980.67% |
| 2005-12-31 | -3659.83% |
| 2005-09-30 | -2097.22% |
| 2005-03-31 | -1394.84% |
| 2004-12-31 | -671.93% |
| 2004-09-30 | -1429.95% |
| 2004-06-30 | -1318.57% |
| 2004-03-31 | -600.00% |
| 2003-12-31 | -640.96% |
| 2003-09-30 | -952.33% |
| 2003-06-30 | -1565.14% |
| 2003-03-31 | -744.68% |
| 2002-12-31 | -1339.18% |
| 2002-09-30 | -2650.54% |
